Recardio announces conclusion of interim analysis of Phase 2 in AMI
Category: #health  By Pankaj Singh  Date: 2020-02-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Recardio announces conclusion of interim analysis of Phase 2 in AMI

 

  • The study of combination of dutogliptin and filgrastim involved approximately 120 patient enrollments.
  • The company expects the trial completion by year end.

Treatment trials across various pharmaceutical companies are on the go lately. Supporting the same, Recardio, one of the clinical stage life science companies, reportedly announced the completion of an interim analysis of its Phase 2 study of dutogliptin and filgrastim, combined, in early recovery post-myocardial infarction. Moreover, it has been estimated that the patient recruitment for the study is still continuing at all the participating centers of the company.

The placebo-controlled Phase 2 study is expected to enroll nearly 120 patients globally. Apparently, the study is planned to evaluate the efficiency and safety of the company’s dutogliptin, which is used to restore the dropped myocardial function in patients experiencing severe heart attack and percutaneous coronary intervention.

Further, the analysis was carried out in agreement with the analysis’ Data Safety Monitoring Board, which produced an authentication of the study and its continuation, prompting participating trial centers to carry on their patient recruitment operations, globally. 

Speaking on the completion of the analysis, Recardio’s Executive Chairman, Roman Schenk reportedly quoted that the interim analysis has been a crucial milestone for completion of the study. The company is highly encouraged by the efforts of several clinical investigators and is determined to conclude the trial by this year end.

It has been reported that Recardio’s regenerative therapeutic approach to reduce and repair heart muscle injury constitutes recruiting, mobilizing, and homing stem cells in-vivo by making use of cytokines and inhibitors.

Headquartered in California, Recardio Inc., is a clinical stage life science company which focuses on therapies involving the cardiovascular, oncology, and infectious disorders. The company’s lead drug, dutogliptin has demonstrated considerable effects in activating vivid chemokines essential for treatment of different cardiovascular diseases.

Source credits: https://recardio.eu/2020/02/recardio-completes-interim-analysis-of-phase-2-in-ami/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...